Methadone use in patients with chronic renal disease.

The Rockefeller University, 1230 York Avenue, New York, New York 10021 U.S.A.; the Office of Primary Health Care Education, Office of the Dean, College of Medicine and Dentistry of New Jersey, New Jersey Medical School, 100 Bergen Street, Newark, New Jersey 07103 U.S.A.
Drug and Alcohol Dependence (Impact Factor: 3.14). 04/1980; 5(3):197-205. DOI:10.1016/0376-8716(80)90180-5
Source: PubMed

ABSTRACT Methadone disposition was studied in three patients receiving chronic methadone treatment and having chronic renal disease: one oliguric patient during peritoneal dialysis, one anuric patient on hemodialysis, and one patient following renal transplantation. In all three patients plasma levels of methadone remained within the desired therapeutic range (0.09--0.68 microgram/ml) for the doses received (40-50 mg/day). Elimination of methadone and its metabolites was almost exclusively by the fecal route in the anuric patient. Less than 1% of the daily dose was removed by peritoneal dialysis or hemodialysis. There was no laboratory or clinical evidence for accumulation of either methadone or its metabolites, suggesting that methadone is an appropriate narcotic to use in patients with renal disease.

0 0
1 Bookmark
  • [show abstract] [hide abstract]
    ABSTRACT: Opioids are commonly prescribed to patients with chronic pain associated with end-stage renal disease requiring hemodialysis. The stability of opioid analgesia during dialysis may vary between different opioids. No studies to date have corroborated this clinical observation by directly comparing plasma concentrations of different opioids during dialysis. We compared changes in peri-dialysis plasma concentrations of two pharmacokinetically distinct opioids, methadone and hydromorphone (HM). Fourteen dialysis patients with chronic pain received either methadone or HM for at least two weeks prior to beginning the study. Blood samples were obtained immediately before, during and after hemodialysis in two separate dialysis sessions, one week apart, and were analyzed for opioid concentrations. Methadone plasma concentrations were more stable during hemodialysis compared to HM: the mean percent change of methadone plasma levels was 14.9±8.2% (±SD) compared to 55.1±8.1% in the HM treatment group, a difference of 40.2% (95% C.I. 17.14-63.14). The mean plasma clearance of methadone was 19.9±8.5 ml/min (±SD) compared to 105.7±8.3 ml/min for HM, a difference of 85.7 ml/min (95% C.I. 61.9-109.1). There were no differences between the two opioid groups in pain scores, side effect profile and quality of life. Methadone therapy was not associated with an increased rate of adverse events. If confirmed by larger clinical studies, methadone could be considered as one of the opioids of choice in dialysis patients.
    Pain 08/2013; · 5.64 Impact Factor
  • Source
    [show abstract] [hide abstract]
    ABSTRACT: Chronic kidney disease is common and patients with many co-morbid conditions frequently have to undergo surgical procedures and, therefore, require effective pain management. The pharmacokinetics of various analgesic agents are not well studied in patients with chronic kidney disease and the risk of accumulation of the main drug or their metabolites, resulting in serious adverse events, is a common scenario on medical and surgical wards. It is common for these patients to be cared for by 'non-nephrologists' who often prescribe the standard dose of the commonly used analgesics, without taking into consideration the patient's kidney function. It is important to recognize the problems and complications associated with the use of standard doses of analgesics, and highlight the importance of adjusting analgesic dosage based on kidney function to avoid complications while still providing adequate pain relief.
    F1000Research. 01/2013; 2.
  • [show abstract] [hide abstract]
    ABSTRACT: There is increasing international attention in efforts to integrate palliative care principles, including pain and symptom management, into the care of patients with advanced chronic kidney disease (CKD). The purpose of this scoping review was to determine the extent, range, and nature of research activity around pain in CKD with the goal of (i) identifying gaps in current research knowledge; (ii) guiding future research; and (iii) creating a rich database of literature to serve as a foundation of more detailed reviews in areas where the data are sufficient. This review will specifically address the epidemiology of pain in CKD, analgesic use, pharmacokinetic data of analgesics, and the management of pain in CKD. It will also capture the aspects that pertain to specific pain syndromes in CKD such as peripheral neuropathy, carpal tunnel syndrome, joint pain, and autosomal dominant polycystic kidney disease.
    Seminars in Dialysis 02/2014; · 2.25 Impact Factor

M J Kreek